New peptide and protein drugs

Pharmacy World and Science

Volumn 18, Issue 3, 1996, Pages 87-93

  Vermeij, P ^a   Blok, D ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

biotechnology products; cytokines; growth factors; monoclonal antibodies; peptides; vaccines

Indexed keywords

CYTOKINE; GROWTH FACTOR; HORMONE; MONOCLONAL ANTIBODY; PEPTIDE; PROTEIN; VACCINE;

BIOTECHNOLOGY; DRUG DEVELOPMENT; DRUG INDUSTRY; ETHICS; PHARMACIST; REVIEW;

ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; CLINICAL TRIALS; CYTOKINES; HUMAN GROWTH HORMONE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PHARMACISTS; PLASMINOGEN ACTIVATORS; VACCINES, DNA;

EID: 0029898879     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00417755     Document Type: Review

References (53)

1. Köhler G, Milstein C. Derivatives of specific antibody-producing tissue culture and tumour lines by cell fusions. Eur J Immunol. 1976; 6: 511-19.
2. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
3. Watson JD, Tooze J, Kurtz DT. The science used in the recombinant DNA-industry. In: Recombinant DNA, a short course. Scientific American Books. New York, 1983: W.H. Freeman and Company. 231-241.
4. Dinarello, CA. Modalities for reduced interleukin-1 activity in disease. TIPS 1993; 14: 155-159.
5. Olijve W. Biotechnologie en geneesmiddelenonderzoek (Biotechnology and drug discovery). Pharm Weekbl 1995; 130: 676-82.
6. Anon. Biotechnology medicines in development. 1993 Survey report. Washington, DC: Pharmaceutical Manufacturers Association; 1993.
7. Santell JP. Projecting future drug expenditures. Am J Hosp Pharm 1995; 52: 158.
8. Silverman JB. A biotech primer. In: A biotech primer. New York: Wertheim Schroder & Co, 1992: 1-32.
9. Anonymous. Biotechnology. Pharm Weekbl 1995; 130: 881.
10. Bruton OC. Agammaglobulinemias. Pediatrics 1952; 9: 722-8.
11. Dwyer JM. Manipulating the immune system with immune globulin. New Engl J Med 1992; 326: 107-16.
12. Rees J. Guillain-Barré syndrome. Clinical Manifestations and directions for treatment. Drugs 1995; 49: 912-20.
13. Timmerhuis TPJ, Brouwer PJAM. Intraveneus toegediend immunoglobuline ter behandeling van neurologische aandoeningen. Pharm Weekbl 1994; 129: 732-6.
14. 1-antitrypsin deficiency. Am J Health-Syst Ph 1995; 52: 481-9.
15. 1-antitrypsin deficiency. J Intern Med 1989; 225: 69-72.
16. 1-antitrypsine deficiency. J Clin Invest 1989; 84: 1349-54.
17. 1-antitrypsin concentrate. Vox Sang. 1987; 52: 291-7.
18. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346: 336-40.
19. Tami JA, Parr MD, Brown SA, Thompson JS. Monoclonal antibody technology. Am J Hosp Pharm 1986; 43: 2816-25.
20. Kosmas C, Kalofonos H, Epenetos AA. Monoclonal antibodies. Future Potential in Cancer Chemotherapy. Drugs 1989; 38: 645-57.
21. Bach JF, Chatenoud L. Immunologic Monitoring of Orthoclone OKT3-treated Patients: The Problem of Antimonoclonal Immune Response. Transplantation Proceedings 1987; 19: 17-20.
22. Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Garrett E et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclone antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1991; 324: 429-36.
23. Hurley JC. Sepsis management and antiendotoxin therapy after nebacumab. drugs 1994; 47: 855-61.
24. Bakke OM, Manocchia M, Abajo F de, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther 1995; 58: 108-17.
25. Susla GM, Dew RB. Antiendotoxin monoclonal antibodies. What future now? Drug Safety 1994; 11:215-22.
26. Faults D, Sorkin EM, Abciximab (c7E3 Fab). A Review of its Pharmacology and Therapeutic Potential in Ischaemic Heart Disease. Drugs 1994; 48: 583-98.
27. Derkx B, Taminiau J, Radema S, Stronkhorst A, Wortel C, Tytgat GNJ et al. Tumour necrosis factor antibody treatment in Crohn's disease. Lancet 1993; 342: 173-4.
28. Elliot MJ, Maini RN, Feldmann M, Kladen JR, Natoni C, Smolen JS et al. Randomised double blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1104-10.
29. Knight DM, Trink H, Le J, Siegel S, Shealy D, Mc Donough M et al. Construction and initial characterization of a mouse-human anti-TNF-antibody. Molecular Immunology 1993; 30: 1443.
30. Hoefnagel CA. Radionuclide therapy revisited. Eur J Nucl Med 1991; 18: 408-31.
31. Collier BD, Foley WD. Current imaging strategies for colorectal cancer. J Nucl Med 1993; 34: 537-40.
32. Krag DN. Clinical utility of immunoscintigraphy in managing ovarian cancer. J Nucl Med 1993; 34: 545-48.
33. Serafini AN. From monoclonal antibodies to peptides and molecular recognition units: An Overview. J Nucl Med 1993; 34: 533-36.
34. Jörgensen JOL, Pedersen SA, Thuesen L, Jorgensen J, Ingemann-Hansen T, Skakkebaek NE et al. Beneficial effects of growth hormone treatment in growth hormone deficient adults. Lancet 1989; i: 1221-5.
35. Salomon F, Cuneo RC, Hesp R, Sönksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321: 1797-1803.
36. Powrie J, Weissberger A, Sönksen P. Growth Hormone replacement therapy for growth hormone-deficient adults. Drugs 1995; 49: 656-63.
37. Brook CGD. Who's for growth hormone? Br Med J 1991; 304: 131-2.
38. Darendeliler F, Hindmarsh PC, Brook CGD. Dose response curves for treatment with biosynthetic human growth hormone. J Endocrinol 1990; 125: 311-6.
39. Wit JM, Boersma B, De MuinckKeizer-Schrama SMPF, Nienhuis HE, Oostdijk W, Otten BJ, et al. Long term results of growth hormone therapy in children with short stature, subnormal growth rate and normal growth hormone response to secretagogues. Clin Endocrinology 1995; 42: (in press).
40. Stanhoper, Preece MA, Hamill G. Does growth hormone treatment improve final height attainment of children with intrauterin growth retardation? Arch Dis Child 1991; 66: 1180-3.
41. Cianfarani S, Vaccaro F, Boscherini B. What is the rationale for growth hormone therapy in Turner's syndrome? Lancet 1994; 344: 114-115.
42. Bryson HM, Sorkin EM. Dornase Alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis. Drugs 1994; 48: 894-906.
43. De Renzo EC, Suteri PK, Hutchings BL, Bell PH. Preparation and certain properties of highly purified streptokinase. J Biol Chem 1967; 137: 533-42.
44. Anderson JL. Development and evaluation of anisoylated streptokinase activator complex (APSAC) as a second generation thrombolytic agent. J Am Coll Cardiol 1987; 10: 22B-7B.
45. Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CH et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E.coli. Nature 1983; 301: 214-21.
46. International joint Efficacy Comparison of Thrombolytics. Randomised, double blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995; 346: 329-36.
47. Verstraete M. Use of thrombolytic drugs in non-coronary disorders. Drugs 1989; 38: 801-21.
48. Schaik BAM van. Myocardinfarct 1993, nieuwe therapieen. Pharm Weekbl 1994; 129: 18-20.
49. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12, 490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71.
50. ISIS-3: A randomised comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin and heparin versus heparin alone among 41, 229 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-70.
51. The Gusto Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-22.
52. Ketley D, Woods KL. Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction. Lancet 1993; 342: 891-4.
53. Fibrinolytic Therapy Trialists (FTT) collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322.